Exagen Inc (XGN)

$2.7

-0.02

(-0.74%)▲

Market is closed - opens 7 PM, 11 Oct 2024

Performance

  • $2.65
    $2.76
    $2.70
    downward going graph

    1.85%

    Downside

    Day's Volatility :3.99%

    Upside

    2.17%

    downward going graph
  • $1.30
    $3.71
    $2.70
    downward going graph

    51.84%

    Downside

    52 Weeks Volatility :64.95%

    Upside

    27.22%

    downward going graph

Returns

PeriodExagen IncSector (Health Care)Index (Russel 2000)
3 Months
46.24%
4.8%
0.0%
6 Months
85.03%
8.3%
0.0%
1 Year
28.91%
17.0%
0.0%
3 Years
-78.17%
20.8%
-20.8%

Highlights

Market Capitalization
47.3M
Book Value
$1.01
Earnings Per Share (EPS)
-0.97
Wall Street Target Price
6.25
Profit Margin
-30.56%
Operating Margin TTM
-17.17%
Return On Assets TTM
-17.41%
Return On Equity TTM
-69.97%
Revenue TTM
56.7M
Revenue Per Share TTM
3.16
Quarterly Revenue Growth YOY
6.6000000000000005%
Gross Profit TTM
21.3M
EBITDA
-13.8M
Diluted Eps TTM
-0.97
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.96
EPS Estimate Next Year
-0.83
EPS Estimate Current Quarter
-0.34
EPS Estimate Next Quarter
-0.34

Analyst Recommendation

Buy
    80%Buy
    20%Hold
    0
    0%Sell
Based on 10 Wall street analysts offering stock ratings for Exagen Inc(by analysts ranked 0 to 5 stars)
Based on 10 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
8
8
8
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 131.48%

Current $2.70
Target $6.25

Company Financials

FY18Y/Y Change
Revenue
32.4M
↑ 21.01%
Net Income
-8.0M
↓ 68.74%
Net Profit Margin
-24.7%
↑ 70.91%
FY19Y/Y Change
Revenue
40.4M
↑ 24.5%
Net Income
-12.0M
↑ 50.25%
Net Profit Margin
-29.81%
↓ 5.11%
FY20Y/Y Change
Revenue
42.0M
↑ 3.93%
Net Income
-16.7M
↑ 38.62%
Net Profit Margin
-39.75%
↓ 9.94%
FY21Y/Y Change
Revenue
48.3M
↑ 15.07%
Net Income
-26.9M
↑ 60.91%
Net Profit Margin
-55.59%
↓ 15.84%
FY22Y/Y Change
Revenue
45.6M
↓ 5.66%
Net Income
-47.4M
↑ 76.48%
Net Profit Margin
-104.0%
↓ 48.41%
FY23Y/Y Change
Revenue
52.5M
↑ 15.33%
Net Income
-23.7M
↓ 50.01%
Net Profit Margin
-45.08%
↑ 58.92%
Q1 FY23Q/Q Change
Revenue
11.2M
↓ 12.52%
Net Income
-8.3M
↓ 42.12%
Net Profit Margin
-73.98%
↑ 37.84%
Q2 FY23Q/Q Change
Revenue
14.1M
↑ 25.89%
Net Income
-5.0M
↓ 39.66%
Net Profit Margin
-35.46%
↑ 38.52%
Q3 FY23Q/Q Change
Revenue
13.4M
↓ 5.1%
Net Income
-5.4M
↑ 8.02%
Net Profit Margin
-40.36%
↓ 4.9%
Q4 FY23Q/Q Change
Revenue
13.8M
↑ 2.6%
Net Income
-5.6M
↑ 2.92%
Net Profit Margin
-40.49%
↓ 0.13%
Q1 FY24Q/Q Change
Revenue
14.4M
↑ 4.72%
Net Income
-3.4M
↓ 39.71%
Net Profit Margin
-23.31%
↑ 17.18%
Q2 FY24Q/Q Change
Revenue
15.1M
↑ 4.5%
Net Income
-3.0M
↓ 11.73%
Net Profit Margin
-19.69%
↑ 3.62%
FY18Y/Y Change
Total Assets
28.9M
↑ 41.67%
Total Liabilities
35.6M
↑ 42.32%
FY19Y/Y Change
Total Assets
88.3M
↑ 205.71%
Total Liabilities
32.7M
↓ 8.34%
FY20Y/Y Change
Total Assets
78.4M
↓ 11.25%
Total Liabilities
36.5M
↑ 11.9%
FY21Y/Y Change
Total Assets
123.4M
↑ 57.51%
Total Liabilities
38.5M
↑ 5.4%
FY22Y/Y Change
Total Assets
86.2M
↓ 30.15%
Total Liabilities
43.8M
↑ 13.64%
FY23Y/Y Change
Total Assets
56.9M
↓ 33.96%
Total Liabilities
34.3M
↓ 21.73%
Q1 FY23Q/Q Change
Total Assets
79.2M
↓ 8.1%
Total Liabilities
43.3M
↓ 1.06%
Q2 FY23Q/Q Change
Total Assets
64.2M
↓ 19.0%
Total Liabilities
32.3M
↓ 25.45%
Q3 FY23Q/Q Change
Total Assets
60.9M
↓ 5.06%
Total Liabilities
33.4M
↑ 3.56%
Q4 FY23Q/Q Change
Total Assets
56.9M
↓ 6.54%
Total Liabilities
34.3M
↑ 2.47%
Q1 FY24Q/Q Change
Total Assets
50.8M
↓ 10.78%
Total Liabilities
30.8M
↓ 10.02%
Q2 FY24Q/Q Change
Total Assets
49.3M
↓ 2.95%
Total Liabilities
31.7M
↑ 2.94%
FY18Y/Y Change
Operating Cash Flow
-9.3M
↓ 15.2%
Investing Cash Flow
-199.0K
↓ 60.98%
Financing Cash Flow
11.4M
↓ 40.37%
FY19Y/Y Change
Operating Cash Flow
-9.7M
↑ 4.41%
Investing Cash Flow
-103.0K
↓ 48.24%
Financing Cash Flow
68.7M
↑ 501.72%
FY20Y/Y Change
Operating Cash Flow
-14.1M
↑ 45.03%
Investing Cash Flow
-455.0K
↑ 341.75%
Financing Cash Flow
-97.0K
↓ 100.14%
FY21Y/Y Change
Operating Cash Flow
-20.3M
↑ 43.92%
Investing Cash Flow
-2.4M
↑ 431.87%
Financing Cash Flow
64.7M
↓ 66783.51%
FY22Y/Y Change
Operating Cash Flow
-32.1M
↑ 58.59%
Investing Cash Flow
-4.3M
↑ 78.43%
Financing Cash Flow
-489.0K
↓ 100.76%
Q1 FY23Q/Q Change
Operating Cash Flow
-9.7M
↑ 70.02%
Investing Cash Flow
-396.0K
↓ 2.46%
Financing Cash Flow
-62.0K
↓ 64.16%
Q2 FY23Q/Q Change
Operating Cash Flow
-10.2M
↑ 4.15%
Investing Cash Flow
-322.0K
↓ 18.69%
Financing Cash Flow
-10.2M
↑ 16419.35%

Technicals Summary

Sell

Neutral

Buy

Exagen Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Exagen Inc
Exagen Inc
-7.8%
85.03%
28.91%
-78.17%
-79.11%
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
-4.29%
-5.85%
5.31%
-22.54%
74.35%
Agilent Technologies Inc.
Agilent Technologies Inc.
4.9%
0.44%
27.81%
-3.48%
95.68%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
-4.0%
4.45%
20.78%
3.56%
113.51%
Danaher Corp.
Danaher Corp.
-2.0%
9.5%
23.1%
-9.88%
94.03%
Iqvia Holdings Inc.
Iqvia Holdings Inc.
-2.73%
-4.44%
13.54%
-4.78%
57.91%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Exagen Inc
Exagen Inc
NA
NA
NA
-0.96
-0.7
-0.17
NA
1.01
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
47.18
47.18
5.0
10.57
0.63
0.23
NA
19.16
Agilent Technologies Inc.
Agilent Technologies Inc.
30.04
30.04
3.12
5.24
0.25
0.08
0.01
20.53
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
37.17
37.17
2.22
21.73
0.14
0.05
0.0
124.17
Danaher Corp.
Danaher Corp.
49.49
49.49
2.66
7.59
0.08
0.04
0.0
68.92
Iqvia Holdings Inc.
Iqvia Holdings Inc.
29.67
29.67
1.12
11.2
0.23
0.05
NA
36.83
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Exagen Inc
Exagen Inc
Buy
$47.3M
-79.11%
NA
-30.56%
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
Buy
$39.1B
74.35%
47.18
22.34%
Agilent Technologies Inc.
Agilent Technologies Inc.
Buy
$41.6B
95.68%
30.04
21.75%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
Buy
$228.9B
113.51%
37.17
14.69%
Danaher Corp.
Danaher Corp.
Buy
$194.4B
94.03%
49.49
17.83%
Iqvia Holdings Inc.
Iqvia Holdings Inc.
Buy
$41.7B
57.91%
29.67
9.39%

Insights on Exagen Inc

  • Increasing Revenue

    Revenue is up for the last 4 quarters, 13.41M → 15.06M (in $), with an average increase of 3.8% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 3 quarters, -5.57M → -2.96M (in $), with an average increase of 39.6% per quarter

  • Vs TMO

    In the last 3 years, Exagen Inc has experienced a drawdown of -78.5%, however Thermo Fisher Scientific, Inc. resisted the overall trend and outperformed by 73.5%

Institutional Holdings

  • RTW INVESTMENTS, LLC

    8.70%

  • COWEN AND COMPANY, LLC

    5.13%

  • Wasatch Advisors LP

    4.38%

  • Silvercrest Asset Management Group LLC

    3.13%

  • Perkins Capital Management Inc

    2.84%

  • Vanguard Group Inc

    2.82%

Company Information

exagen diagnostics, inc. is a patient focused, discovery driven, clia-certified, cap-accredited laboratory with a growing menu of proprietary, internally developed tests focusing in the area of rheumatology and autoimmune diseases. committed to personalized medicine, our avise tests are specifically designed to provide objective information to physicians and patients for more accurate, efficient diagnosis and better disease management. for more information on our company, please visit www.exagen.com. for more information on avise testing services, please visit www.avisetest.com.

Organization
Exagen Inc
Employees
174
CEO
Dr. Tina S. Nova Ph.D.
Industry
Health Services

Discover More

FAQs